Introduction
Transformation, or change in the histologic features of NSCLC has always been a challenge to oncologists. Here we report a case of a new histologic finding from a repeat biopsy specimen from a patient who had initially responded to administration of a programmed death 1 (PD-1) inhibitor but later experienced disease progression.
Case
A 71-year-old man with a 40-pack-year smoking history presented in February 2015 with acute-onset back pain. Magnetic resonance imaging of the spine revealed a T3 vertebral fracture due to a right-sided lung mass invading the T3-T4 neural foramen. A computed tomography (CT) scan showed additional mediastinal lymphadenopathy, disease of the left adrenal gland, and left eighth rib metastasis.
Pathologic example of a specimen from the T3 vertebrae laminectomy revealed squamous cell carcinoma ( Fig. 1A and B) . Postoperatively, the patient had radiation to the right upper lobe and thoracic spine. In June 2015, he began receiving carboplatin/paclitaxel but progressed in the right lung after four cycles.
In September 2015, he began receiving nivolumab. CT scans 3 months into nivolumab therapy showed tumor shrinkage not meeting the Response Evaluation Criteria in Solid Tumors. He experienced improved appetite, consequent weight gain, and reduced back pain, which continued for 10 months. However, subsequent CT scans showed right upper lobe mass enlargement. The findings of CT-guided biopsy of the right upper lobe were reported as adenocarcinoma ( Fig. 2A and B) . Repeat assessment of the laminectomy specimen did not reveal any evidence of adenocarcinoma. Molecular analysis of the new biopsy specimen could not be performed because of insurance issues.
Discussion
Transformation of the histologic features of NSCLC has always been a challenge to oncologists. In 1975, Martini and Melamed defined second primary NSCLC as metachronous tumors with either different or the same histologic features, with an interval of more than 2 years and originating from carcinoma in situ or being a second cancer in a different lobe. 1 Transformation of adenocarcinoma into SCLC has been reported as part of a mechanism of resistance to EGFR tyrosine kinase inhibitors. Tumors often continue to carry the same EGFR mutation even after switching to SCLC. 2 Here we have reported a case of a new pathologic finding from a repeat biopsy specimen after nivolumab. To our knowledge, this is the first report to describe changes in histologic type at the time of progression during treatment with a PD-1 inhibitor, although effects from previous radiation and chemotherapy cannot be excluded. As the initial pathologic examination results were reported from a large resected mass invading the vertebrae, it is unlikely, but still possible, that the mixed squamous/adenocarcinoma histologic type was missed.
Data on mechanisms of resistance to PD-1 inhibitors are limited. 3 A recent report demonstrated that upregulation of epithelial-to-mesenchymal transitionrelated genes may predict for resistance to PD-1 axis inhibitors. 4 Preclinical studies have suggested that epithelial-to-mesenchymal transition is associated with cancer stem cells. 5 It is only speculative that cancer stem cells may play a role in the switch in histologic type and thus cause secondary resistance to therapy.
Conclusion
Further data are required to ascertain whether such histologic transformation can be one of the mechanisms of resistance to these agents. (A and B) Original T3 vertebrae laminectomy specimen. Rare intercellular bridges was seen, which supports the diagnosis of squamous cell carcinoma based on morphologic findings. Because of decalcification, tumor cells lost antigenicity and tested negative for lung adenocarcinoma cocktail (the results of testing for thyroid transcription factor 1 and napsin A were negative) and negative for squamous cell carcinoma cocktail (cytokeratin 5/6 and protein 63).
